MT-6402, an engineered toxin body (ETB) targeting PD-L1: Interim efficacy and safety data.

Authors

null

Minal A. Barve

Mary Crowley Cancer Research Center, Dallas, TX

Minal A. Barve , Brian Andrew Van Tine , Rebecca A. Redman , Steven Francis Powell , William Jeffery Edenfield , Julio Antonio Peguero , Victoria Meucci Villaflor , Karen Stein , Chris Moore , Rachael Orlandella , Swati Khanna , Joseph Dekker , Silvia Ferrati , Soratree Charoenthongtrakul , Yanning Liu , Kristina Dabovic , David R. Spigel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT04795713

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 2552)

DOI

10.1200/JCO.2023.41.16_suppl.2552

Abstract #

2552

Poster Bd #

394

Abstract Disclosures

Similar Posters

First Author: Frances Jenkins Bennett

First Author: Suzanne Phillips

First Author: Carmen Alvarez-Dominguez